Drugmaker Novo Nordisk's newly approved oral diabetes treatment will cost $772 per month, according to Investor's Business Daily.
Called Rybelsus, the treatment's monthly cost is similar, just slightly higher than Eli Lilly's injectable diabetes treatment, Trulicity, which costs $759 per month.
To help offset some out-of-pocket expenses for patients, Novo Nordisk plans to hand out copay cards, according to Investor's Business Daily.
The drugmaker hopes to attract more Type 2 patients with the oral drug as opposed to alternative injectable treatments.
Diabetes treatment specialists will have access to Rybelsus in October and primary care physicians will have access starting in the first quarter of 2020.
Read the full article here.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries.